Company Filing History:
Years Active: 2000
Title: Innovations in Neuropsychopharmacology by Juan-Carlos Marvizon
Introduction
Juan-Carlos Marvizon, an accomplished inventor based in Madrid, Spain, has made significant contributions to the field of neuropsychopharmacology. His innovative work addresses critical disorders associated with the N-methyl-D-aspartate (NMDA) receptor complex, paving the way for potential treatments that could enhance patient outcomes.
Latest Patents
Marvizon holds a patent titled "Partial agonists of the strychnine insensitive glycine modulatory site." This patent details a method for treating neuropsychopharmacological disorders resulting from excessive activation of the NMDA receptor complex. The method involves administering a compound that acts as a partial agonist at the glycine modulatory sites of the NMDA receptors. Notably, compounds such as 1-aminocyclopropanecarboxylic acid and its associated derivatives are highlighted as effective agents in this innovative treatment approach. Furthermore, his patent encompasses novel injectable pharmaceutical compositions aimed at improving therapeutic efficacy.
Career Highlights
Throughout his career, Juan-Carlos Marvizon has focused on exploring the complex interactions of neurotransmitter systems and developing therapeutic strategies for various neuropsychological disorders. His work has garnered recognition for its potential impact on the treatment landscape for conditions that significantly affect individuals' quality of life.
Collaborations
Marvizon has collaborated with notable professionals in his field, such as Phil Skolnick and Anita H. Lewin. These collaborations reflect a commitment to advancing scientific knowledge and developing innovative treatment methodologies. Working alongside esteemed colleagues enhances the depth and reach of his research efforts.
Conclusion
Juan-Carlos Marvizon's innovative contributions to neuropsychopharmacology exemplify the vital role inventors play in addressing complex medical challenges. His patent on partial agonists for the NMDA receptor complex represents a promising avenue for the treatment of neuropsychopharmacological disorders. As research in this area continues to evolve, the impact of his innovations will likely contribute significantly to future therapeutic strategies.